The prevalence and cost of unapproved uses of top-selling orphan drugs
about
Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act CoverageProfitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control StudyOutcomes of off-label drug uses in hospitals: a multicentric prospective studyPharmaceutical pricing, cost containment and new treatments for rare diseases in children.Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model.Personalizing health care: feasibility and future implications.Payers' Views of the Changes Arising through the Possible Adoption of Adaptive PathwaysOff-label use of orphan medicinal products: a Belgian qualitative study.Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?Saving orphan drug legislations: misconceptions and clarifications.Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field.
P2860
Q28468454-467C4607-AF2E-493F-9F29-1E11BE8F5B5FQ28552860-14C858AB-B069-4283-8668-459B4E398E17Q34347118-60DF8D74-BE7C-4B9C-982A-4ADF8341A685Q34459782-6EA2E932-3724-4EA6-9C12-081E48DFBEFAQ34572340-F6A57693-251C-4478-8C4A-FE5A0553B7E3Q34938911-D920744F-3789-4306-A46B-BB96193A334EQ37290101-104206B8-C974-4B62-B872-BB0BA048993DQ37377924-40C467CE-10AD-4333-9979-87EFE49AAE6BQ37441285-2508257D-5331-4FB1-A520-E0BD13B4C831Q37566934-96AFEB4F-E2C7-4DFA-92D5-E53E6FE5B5FBQ38696997-CB7EC933-CE7A-4F4E-88A9-B220DE3C636FQ39968188-10959B76-3CD3-4756-ADE2-FF40EDD5DD7C
P2860
The prevalence and cost of unapproved uses of top-selling orphan drugs
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The prevalence and cost of unapproved uses of top-selling orphan drugs
@ast
The prevalence and cost of unapproved uses of top-selling orphan drugs
@en
The prevalence and cost of unapproved uses of top-selling orphan drugs
@en-gb
The prevalence and cost of unapproved uses of top-selling orphan drugs
@nl
type
label
The prevalence and cost of unapproved uses of top-selling orphan drugs
@ast
The prevalence and cost of unapproved uses of top-selling orphan drugs
@en
The prevalence and cost of unapproved uses of top-selling orphan drugs
@en-gb
The prevalence and cost of unapproved uses of top-selling orphan drugs
@nl
altLabel
The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
@en
prefLabel
The prevalence and cost of unapproved uses of top-selling orphan drugs
@ast
The prevalence and cost of unapproved uses of top-selling orphan drugs
@en
The prevalence and cost of unapproved uses of top-selling orphan drugs
@en-gb
The prevalence and cost of unapproved uses of top-selling orphan drugs
@nl
P2093
P2860
P3181
P1433
P1476
The prevalence and cost of unapproved uses of top-selling orphan drugs
@en
P2093
Daniel H Solomon
Jerry Avorn
Jessica A Myers
Raisa Levin
Wolfgang C Winkelmayer
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0031894
P407
P577
2012-01-01T00:00:00Z